DGIdb - ETOPOSIDE Drug Record

ETOPOSIDE chembl:CHEMBL44657 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NSC-141540
VP-16-213
TOPOSAR
VEPESID
ETOPOSIDE
TRANS-ETOPOSIDE
ETOPOSIDO
VP-16
VEPESID®
ETOPOSIDUM
9-((4,6-O-ETHYLIDINE-BETA-D-GLUCOPYRANOSYL)OXY)-5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,4-DIMETHYLOXYPHENYL)FURO(3',4'':6,7)NAPTHO-(2,3-D)-1,3-DIOXOL-6(5AH)-ONE
ETOPOPHOS®
VP 16-213
4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-BETA-D-GLUCOPYRANOSIDE)
(−)-ETOPOSIDE
TOPOSAR®
4-DEMETHYLEPIPODOPHYLLOTOXIN Β-D-ETHYLIDENEGLUCOSIDE
4-DEMETHYLEPIPODOPHYLLOTOXIN BETA-D-ETHYLIDENEGLUCOSIDE
(-)-ETOPOSIDE
pubchem.compound:36462
drugbank:00773
chembl:CHEMBL44657
chemidplus:33419-42-0
rxcui:4179

Drug Info:

FDA Approval	1983
Drug Class	small molecule
Drug Indications	Antineoplastic Agents
Drug Categories	podophyllotoxin derivatives
Drug Categories	podophyllotoxin
Drug Categories	lignans
Drug Categories	glucosides
Year of Approval	1983
Drug Class	antineoplastic agents
Drug Categories	cardiotoxic antineoplastic agents
Drug Categories	cytochrome p-450 cyp1a2 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp2e1 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp3a4 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 cyp3a5 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	p-glycoprotein substrates with narrow therapeutic index
Drug Categories	ugt1a1 substrates
Drug Categories	ugt1a1 substrates with narrow therapeutic index

(9 More Sources)

Publications:

Kamal A et al., 2013, Synthesis and study of benzothiazole conjugates in the control of cell proliferation by modulating Ras/MEK/ERK-dependent pathway in MCF-7 cells., Bioorg Med Chem Lett
Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
Stachelek et al., 2015, YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors., Mol. Cancer Res.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Jeffrey et al., 2002, Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor alpha family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase., Cancer Res.
Hida et al., 2004, Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis., J. Lab. Clin. Med.
Dunlap N et al., 2014, Synthesis and evaluation of ether-linked demethylepipodophyllotoxin dimers., Bioorg Med Chem Lett
Chee GL et al., 2010, A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II., Bioorg Med Chem
Hasinoff et al., 2008, The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds., Bioorg. Med. Chem.
Asano et al., 1996, Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide., Oncol. Res.
Dong G et al., 2012, New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations., J Med Chem
Chen W et al., 2014, Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomeraseIIα and antitumor agents., Eur J Med Chem
Hao H et al., 2015, Design and synthesis of 2-phenylnaphthalenoids and 2-phenylbenzofuranoids as DNA topoisomerase inhibitors and antitumor agents., Eur J Med Chem
Wang MJ et al., 2014, Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents., J Med Chem
Negi A et al., 2015, Imine/amide-imidazole conjugates derived from 5-amino-4-cyano-N1-substituted benzyl imidazole: Microwave-assisted synthesis and anticancer activity via selective topoisomerase-II-α inhibition., Bioorg Med Chem
Shankaraiah N et al., 2015, One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents., Bioorg Med Chem Lett
Chaniyara R et al., 2013, Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition., J Med Chem
de Lucio et al., 2005, Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha., Cancer Sci.
Baviskar AT et al., 2013, Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity., Bioorg Med Chem
Genès C et al., 2011, Synthesis and biological evaluation of N-substituted benzo[c]phenanthrolines and benzo[c]phenanthrolinones as antiproliferative agents., Eur J Med Chem
Oppegard LM et al., 2012, Inhibition of human topoisomerases I and II by simocyclinone D8., J Nat Prod
Su TL et al., 2006, Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity., J Med Chem
Furbacher TR et al., 2001, Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica., J Nat Prod
Lemster T et al., 2009, Photochemical electrocyclisation of 3-vinylindoles to pyrido[2,3-a]-, pyrido[4,3-a]- and thieno[2,3-a]-carbazoles: design, synthesis, DNA binding and antitumor cell cytotoxicity., Eur J Med Chem
Liu LP et al., 2014, Topoisomerase II inhibitors from the roots of Stellera chamaejasme L., Bioorg Med Chem
Zhou Y et al., 2013, Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives., Bioorg Med Chem Lett
Uesaka et al., 2007, Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity., J. Neurooncol.
Yadav AA et al., 2015, Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs., Bioorg Med Chem
Baviskar AT et al., 2015, Switch in Site of Inhibition: A Strategy for Structure-Based Discovery of Human Topoisomerase IIα Catalytic Inhibitors., ACS Med Chem Lett
de Oliveira Figueiredo P et al., 2014, Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIα by its cytotoxic β-carboline alkaloids., Bioorg Med Chem Lett
Zhao W et al., 2014, A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation., Bioorg Med Chem
Nitiss et al., 1998, The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II., Biochemistry
Tan S et al., 2013, Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation., Eur J Med Chem
He S et al., 2015, Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors., ACS Med Chem Lett
López-Lázaro et al., 2005, Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients., J. Nat. Prod.
Li YB et al., 2013, Discovery, synthesis and biological evaluation of cycloprotoberberine derivatives as potential antitumor agents., Eur J Med Chem
Bar FM et al., 2009, Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors., J Nat Prod
Qiu J et al., 2015, Synthesis, biological evaluation and modeling studies of terphenyl topoisomerase IIα inhibitors as anticancer agents., Eur J Med Chem
Baviskar AT et al., 2011, N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase., J Med Chem
Aleksić M et al., 2012, Novel substituted benzothiophene and thienothiophene carboxanilides and quinolones: synthesis, photochemical synthesis, DNA-binding properties, antitumor evaluation and 3D-derived QSAR analysis., J Med Chem
Mariani A et al., 2015, Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules., J Med Chem
Aleksić M et al., 2014, Anilides and quinolones with nitrogen-bearing substituents from benzothiophene and thienothiophene series: synthesis, photochemical synthesis, cytostatic evaluation, 3D-derived QSAR analysis and DNA-binding properties., Eur J Med Chem
Winnicka et al., Cardiac glycosides in cancer research and cancer therapy., Acta Pol Pharm
Asano et al., 1996, Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene., Biochem. J.
Liu JF et al., 2013, Synthesis and cytotoxic activity on human cancer cells of carbamate derivatives of 4β-(1,2,3-triazol-1-yl)podophyllotoxin., Eur J Med Chem
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Hajbi Y et al., 2010, Synthesis and biological activities of new furo[3,4-b]carbazoles: potential topoisomerase II inhibitors., Eur J Med Chem
Zhang X et al., 2013, The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase., Bioorg Med Chem
Kamal A et al., 2015, Design and synthesis of dithiocarbamate linked β-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability., Bioorg Med Chem
Chen TC et al., 2015, Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents., Eur J Med Chem
Kamal A et al., 2012, Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents., Bioorg Med Chem
Moneypenny et al., 2006, MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells., Carcinogenesis
McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
Huang ZH et al., 2013, Design, synthesis and biological evaluation of novel mansonone E derivatives prepared via CuAAC click chemistry as topoisomerase II inhibitors., Eur J Med Chem
Jiménez-Alonso S et al., 2008, Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors., J Med Chem
Ashour A et al., 2014, Rational design and synthesis of topoisomerase I and II inhibitors based on oleanolic acid moiety for new anti-cancer drugs., Bioorg Med Chem
Sperry J et al., 2009, Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum., Bioorg Med Chem
Brown et al., 1998, Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease., Am. J. Clin. Pathol.
Kishi S et al., 2004, Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia., Blood
Benderra et al., 1998, Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein., Int. J. Oncol.
Lorico et al., 1995, Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene., Cancer Res.
Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
Azarova et al., 2007, Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies., Proc. Natl. Acad. Sci. U.S.A.
Munshi et al., 2001, Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide., Cancer
Whelan et al., 1992, Successful treatment of a primary endodermal sinus tumor of the liver., Cancer
Imamura et al., 1986, [Successful chemotherapy in undescended testicular and extragonadal germ cell tumors: report of 2 cases]., Gan To Kagaku Ryoho
Wu C et al., 2010, Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients., Cancer Res
Jabado et al., 1997, Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors., Blood
Keller et al., 2016, A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma., Mol. Cancer Res.
Lund et al., 2004, Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II., Cancer Lett.
Watanabe et al., 2003, Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1., Drug Metab. Dispos.
Tan et al., 2000, PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway., Proc. Natl. Acad. Sci. U.S.A.
Zhang et al., 1998, Regulation of membrane release in apoptosis., Biochem. J.
Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med
Carrillo et al., 2015, Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells., Mol. Cancer Res.
Bataille F et al., 2003, Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer., Mol Pathol
Brachova P et al., 2013, The consequence of oncomorphic TP53 mutations in ovarian cancer., Int J Mol Sci
Yamagishi et al., 2001, Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis., Endocrinology
Banerjee et al., 1998, Role of E2F-1 in chemosensitivity., Cancer Res.
Russo et al., 2006, E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents., Cancer Res.
Cecchin E et al., 2009, Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan., J Clin Oncol
Ramesh et al., 2010, Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives., Biomed. Chromatogr.
Lankisch TO et al., 2008, Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk., Cancer Epidemiol Biomarkers Prev
Gagné JF et al., 2002, Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)., Mol Pharmacol
Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
Kawato Y et al., 1991, Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11., Cancer Res
Obradovic M et al., 2008, Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer., Pharmacogenomics
Danoff TM et al., 2004, A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia., Pharmacogenomics J
Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk., Clin Cancer Res
Onoue M et al., 2009, UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients., Int J Clin Oncol
Yamasaki S et al., 2015, UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan., Ann Hematol
Hoskins JM et al., 2007, UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters., J Natl Cancer Inst
Kemp DC et al., 2002, Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance., Drug Metab Dispos
Ciotti M et al., 1999, Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus., Biochem Biophys Res Commun
Guillemette C et al., 2000, Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene., Pharmacogenetics
Tao et al., 2003, Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with etoposide., Exp. Hematol.
Eymin et al., 1997, Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide., Cancer Res.
Baltaci et al., 2001, P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours., BJU Int.
Ballestrero et al., 2004, Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells., Clin. Cancer Res.
Mannherz et al., 2005, Activated cofilin colocalises with Arp2/3 complex in apoptotic blebs during programmed cell death., Eur. J. Cell Biol.
Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
Wang et al., 2005, Activation of transforming growth factor-beta1/p38/Smad3 signaling in stromal cells requires reactive oxygen species-mediated MMP-2 activity during bone marrow damage., Stem Cells
Thomadaki et al., PAP modulations in Daudi cells and Molt-3 cells treated with etoposide are mutually associated with morphological evidence of apoptosis., Int. J. Biol. Markers
Fanning et al., 1991, Serial CA 125 levels during chemotherapy for metastatic or recurrent endometrial cancer., Obstet Gynecol

ETOPOSIDE ACTR2

Interaction Score: 2.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15900709

Sources:
NCI
ETOPOSIDE DYNC2H1

Interaction Score: 2.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21118971

Sources:
PharmGKB
ETOPOSIDE PLA2G6

Interaction Score: 1.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
ETOPOSIDE EIF4E

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11956083

Sources:
NCI
ETOPOSIDE TOP2A

Interaction Score: 0.66

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
25466187 20006518 18258442 8823806 22867019 25240702 26291037 25003995 26216018 26292628 23360284 16271071 23920485 21435753 22867097 16759114 11678653 19386396 24931277 23566520 17361331 25922181 25941559 24507920 24775914 9485461 23353750 25815139 16309315 24012683 19691293 25800514 21644529 22620261 25945730 24334150 17514873 8870683 23711769 11752352 20863598 24095018 26264845 25799376 22364746 16377807 9494516 23968711 18816045 24326278 19783445 9426516

Sources:
NCI TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
ETOPOSIDE PAPOLA

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15503822

Sources:
NCI
ETOPOSIDE BTF3P11

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11459812

Sources:
NCI
ETOPOSIDE SLIT1

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETOPOSIDE UGT1A1

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19364970 19852077 18349289 12181437 17058217 12969965 1651156 18466101 14647407 20562211 19390945 25055799 17728214 12019197 10381366 11037804

Sources:
PharmGKB
ETOPOSIDE GDF15

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10618379

Sources:
NCI
ETOPOSIDE TNFSF13B

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12644023

Sources:
NCI
ETOPOSIDE PGP

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
ETOPOSIDE MUC16

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1988893

Sources:
NCI
ETOPOSIDE AFP

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1382827 2427033

Sources:
NCI
ETOPOSIDE MYCN

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12439032

Sources:
NCI
ETOPOSIDE TOP2B

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA topoisomerase II inhibitor

Direct Interaction yes

PMIDs:
17578914 16309315 25945730 26264845 22364746

Sources:
DTC TTD DrugBank ChemblInteractions
ETOPOSIDE UGT1A10

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12695347

Sources:
NCI
ETOPOSIDE E2F1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9766655 16849574

Sources:
NCI
ETOPOSIDE IGF2

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15019164

Sources:
NCI
ETOPOSIDE NCOA3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ETOPOSIDE KLK3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11391599

Sources:
NCI
ETOPOSIDE ERCC2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETOPOSIDE GSTT1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETOPOSIDE ITGAL

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9389690

Sources:
NCI
ETOPOSIDE BRCA2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
26116172

Sources:
JAX-CKB
ETOPOSIDE TYMSOS

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETOPOSIDE DDIT3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9044846

Sources:
NCI
ETOPOSIDE PLA2G1B

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9716508

Sources:
NCI
ETOPOSIDE BCL2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11350408 14977850

Sources:
NCI
ETOPOSIDE ERCC1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETOPOSIDE ABCC1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9472114 7671247

Sources:
NCI
ETOPOSIDE TGFB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16002781

Sources:
NCI
ETOPOSIDE NCOA1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ETOPOSIDE MAPK3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23999041

Sources:
DTC
ETOPOSIDE BAX

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15454884

Sources:
NCI
ETOPOSIDE ATM

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22364746

Sources:
DTC
ETOPOSIDE SLCO1B1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26663398

Sources:
PharmGKB
ETOPOSIDE CHEK1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22364746

Sources:
DTC
ETOPOSIDE GSTP1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12969965

Sources:
PharmGKB
ETOPOSIDE TYMS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETOPOSIDE FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Etoposide + GSK3052230

Indication/Tumor Type lung small cell carcinoma

Response Type sensitive

PMIDs:
23536011

Sources:
JAX-CKB
ETOPOSIDE TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Nutlin-3 + Etoposide

Indication/Tumor Type ovarian cancer

Response Type sensitive

PMIDs:
25964101 14514923 24065105

Sources:
JAX-CKB CIViC
ETOPOSIDE MAPK1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23999041

Sources:
DTC
ETOPOSIDE EGFR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type neuroblastoma

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27216155

Sources:
JAX-CKB
ETOPOSIDE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12969965

Sources:
PharmGKB
ETOPOSIDE GLP1R

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ETOPOSIDE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
ETOPOSIDE CYP2C19

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
ETOPOSIDE CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
ETOPOSIDE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
ETOPOSIDE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
ETOPOSIDE GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00773

Version: 5.1.7

Alternate Names:

ETOPOSIDE DrugBank Drug Name

33419-42-0 CAS Number

Dom-etoposide Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories antineoplastic agents

Publications:

de Lucio et al., 2005, Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha., Cancer Sci.

Uesaka et al., 2007, Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity., J. Neurooncol.

López-Lázaro et al., 2005, Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients., J. Nat. Prod.

TEND: ETOPOSIDE
- Version: 01-August-2011
Alternate Names:

ETOPOSIDE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1983

Publications:
TdgClinicalTrial: ETOPOSIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents

Drug Class small molecule

FDA Approval 1983

Publications:

NCI: ETOPOSIDE

Version: 14-September-2017

Alternate Names:

C491 NCI drug code

Drug Info:

Publications:

Yamagishi et al., 2001, Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis., Endocrinology

Tao et al., 2003, Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with etoposide., Exp. Hematol.

Eymin et al., 1997, Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide., Cancer Res.

DTC: ETOPOSIDE

Version: 02-September-2020

Alternate Names:

CHEMBL44657 ChEMBL Drug ID

Drug Info:

Publications:

López-Lázaro et al., 2005, Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients., J. Nat. Prod.

Mariani A et al., 2015, Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules., J Med Chem

Kamal A et al., 2015, Design and synthesis of dithiocarbamate linked β-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability., Bioorg Med Chem

PharmGKB: etoposide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Cecchin E et al., 2009, Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan., J Clin Oncol

Ramesh et al., 2010, Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives., Biomed. Chromatogr.

Lankisch TO et al., 2008, Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk., Cancer Epidemiol Biomarkers Prev

JAX-CKB: Etoposide

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Stachelek et al., 2015, YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors., Mol. Cancer Res.

Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med

Keller et al., 2016, A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma., Mol. Cancer Res.

CIViC: ETOPOSIDE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Bataille F et al., 2003, Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer., Mol Pathol

Brachova P et al., 2013, The consequence of oncomorphic TP53 mutations in ovarian cancer., Int J Mol Sci

TTD: Etoposide
- Version: 2020.06.01
Alternate Names:

D0B7EB TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103421
- Version: 29-September-2020
Alternate Names:

ETOPOSIDE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL44657
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: ETOPOSIDE
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL44657
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Mechanism of Interaction	DNA topoisomerase II inhibitor
Direct Interaction	yes

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	sensitive

combination therapy	Cisplatin + Etoposide + GSK3052230
Indication/Tumor Type	lung small cell carcinoma
Response Type	sensitive

combination therapy	Nutlin-3 + Etoposide
Indication/Tumor Type	ovarian cancer
Response Type	sensitive

Indication/Tumor Type	neuroblastoma
Response Type	resistant
Approval Status	Preclinical - Cell culture

ETOPOSIDE	DrugBank Drug Name
33419-42-0	CAS Number
Dom-etoposide	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	antineoplastic agents

ETOPOSIDE Drug Record

ETOPOSIDE chembl:CHEMBL44657 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15900709

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21118971

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11956083

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

Sources: NCI TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15503822

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11459812

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19364970 19852077 18349289 12181437 17058217 12969965 1651156 18466101 14647407 20562211 19390945 25055799 17728214 12019197 10381366 11037804

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10618379

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12644023

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1988893

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1382827 2427033

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12439032

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction DNA topoisomerase II inhibitor Direct Interaction yes

PMIDs: 17578914 16309315 25945730 26264845 22364746

Sources: DTC TTD DrugBank ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12695347

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9766655 16849574

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15019164

Sources: NCI

Interaction Types & Directionality:

n/a

PMIDs:
15900709

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21118971

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11956083

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Sources:
NCI TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
15503822

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11459812

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19364970 19852077 18349289 12181437 17058217 12969965 1651156 18466101 14647407 20562211 19390945 25055799 17728214 12019197 10381366 11037804

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10618379

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12644023

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

PMIDs:
1988893

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1382827 2427033

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12439032

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction DNA topoisomerase II inhibitor

Direct Interaction yes

PMIDs:
17578914 16309315 25945730 26264845 22364746

Sources:
DTC TTD DrugBank ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
12695347

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9766655 16849574

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15019164

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11391599

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9389690

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
26116172

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB